跳至主要内容
临床试验/NCT01772576
NCT01772576已完成不适用

RELIANCE 4-FRONT™ Active Fixation Defibrillation Lead Post Market Clinical Follow-Up (PMCF) Study

Boston Scientific Corporation29 个研究点 分布在 11 个国家目标入组 167 人开始时间: 2012年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
167
试验地点
29
主要终点
Complication Free Rate

研究概览

简要总结

The objective of this study is to gather data to establish the chronic safety, performance and effectiveness of the RELIANCE 4-FRONT™ Active Fixation Defibrillation Leads.

详细描述

The RELIANCE 4-FRONT Defibrillation Lead Post Market Clinical Follow-Up Study is a prospective, non-randomized, multi-center, single-group, post market clinical study to establish the chronic safety, performance and effectiveness of the RELIANCE 4-FRONT active fixation defibrillation leads.

A total of 167 patients (including 10 % attrition) are required to evaluate the Primary Endpoint.

Up to 20 Investigational centers located in Europe and Asia Pacific. Lead-related Complication-Free Rate (CFR) from Implant through 3 Months Post-Implant.

Lead-related complications associated with the RELIANCE 4-FRONT active fixation lead will count toward this endpoint.

Lead-related Complication-Free Rate from 3 Months through 15 Months Post-Implant.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Willing and capable of providing informed consent
  • Has an indication for implantation of a single or dual chamber ICD or CRT-D system in their respective geography
  • Subjects planned to be implanted with the RELIANCE 4-FRONT Active Fixation Lead
  • Willing and capable of participating in all testing/ visits associated with this clinical study at an approved clinical study center and at the intervals defined by this protocol
  • Age 18 or above, or of legal age to give informed consent specific to state and national law

排除标准

  • Known or suspected sensitivity to Dexamethasone Acetate (DXA)
  • Mechanical tricuspid heart valve
  • Subject is enrolled in any other concurrent study without prior written approval from Boston Scientific (BSC), with the exception of local mandatory governmental registries and observational studies/registries that are not in conflict and do not affect the following:
  • Schedule of procedures for the RELIANCE 4-Front Study (i.e. should not cause additional or missed visits);
  • RELIANCE 4-Front Study outcome (i.e. involve medications that could affect the heart rate of the subject);
  • Conduct of the RELIANCE 4-Front Study per Good Clinical Practice (GCP)/ International Organization for Standardization (ISO) 14155:2011/ 21 CFR 812/ local regulations
  • Currently on the active heart transplant list
  • Documented life expectancy of less than 12 months
  • Women of childbearing potential who are or might be pregnant at the time of study enrollment (method of assessment upon physician discretion)
  • Currently requiring chronic dialysis

结局指标

主要结局

Complication Free Rate

时间窗: 3-months follow-up

Lead-related Complication-Free Rate (CFR) from Implant through 3 Months Post-Implant.

次要结局

  • Complication Free Rate(3 months through 15 months post implant)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (29)

Loading locations...

相似试验